PriceTargets.com logo

OnKure Therapeutics - OKUR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.50
  • Forecasted Upside: 108.91%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$17.95 As of 10/17/2024 01:00 AM ET
▼ -0.64 (-3.44%)

This chart shows the closing price for OKUR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OnKure Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OKUR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OKUR

Analyst Price Target is $37.50
▲ +108.91% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for OnKure Therapeutics in the last 3 months. The average price target is $37.50, with a high forecast of $40.00 and a low forecast of $35.00. The average price target represents a 108.91% upside from the last price of $17.95.

This chart shows the closing price for OKUR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in OnKure Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/17/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/17/2024HC WainwrightReiterated RatingBuy$40.00
10/10/2024Lifesci CapitalUpgradeStrong-Buy
10/10/2024OppenheimerInitiated CoverageOutperform$35.00
(Data available from 10/17/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/17/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/17/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

OnKure Therapeutics

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.
Read More

Today's Range

Now: $17.95
Low: $16.93
High: $18.38

50 Day Range

MA: N/A

52 Week Range

Now: $17.95
Low: $9.80
High: $86.70

Volume

70,670 shs

Average Volume

27,506 shs

Market Capitalization

$59.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of OnKure Therapeutics?

The following Wall Street analysts have issued research reports on OnKure Therapeutics in the last twelve months: HC Wainwright, Lifesci Capital, and Oppenheimer Holdings Inc..
View the latest analyst ratings for OKUR.

What is the current price target for OnKure Therapeutics?

2 Wall Street analysts have set twelve-month price targets for OnKure Therapeutics in the last year. Their average twelve-month price target is $37.50, suggesting a possible upside of 108.9%. HC Wainwright has the highest price target set, predicting OKUR will reach $40.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $35.00 for OnKure Therapeutics in the next year.
View the latest price targets for OKUR.

What is the current consensus analyst rating for OnKure Therapeutics?

OnKure Therapeutics currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OKUR will outperform the market and that investors should add to their positions of OnKure Therapeutics.
View the latest ratings for OKUR.

What other companies compete with OnKure Therapeutics?

Other companies that are similar to OnKure Therapeutics include Cadrenal Therapeutics, Omeros, Acrivon Therapeutics, Amarin and Procaps Group. Learn More about companies similar to OnKure Therapeutics.

How do I contact OnKure Therapeutics' investor relations team?

OnKure Therapeutics' physical mailing address is 18575 Jamboree Road Suite 275-S, Irvine CA, 92612. The company's listed phone number is 858-283-0280 and its investor relations email address is [email protected]. The official website for OnKure Therapeutics is reneopharma.com. Learn More about contacing OnKure Therapeutics investor relations.